2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2016

9:00AM-11:00AM: Abstract Number: 526

Changes in the Functional Status of the Rheumatoid Arthritis (RA) Population over the Biologic Era

Rheumatoid Arthritis – Clinical Aspects - Poster I: Clinical Characteristics/Presentation/Prognosis

9:00AM-11:00AM: Abstract Number: 542

Changes on Body Composition in Women with Long-Standing Established Rheumatoid Arthritis: Differences By Level of Disease Activity

Rheumatoid Arthritis – Clinical Aspects - Poster I: Clinical Characteristics/Presentation/Prognosis

9:00AM-11:00AM: Abstract Number: 554

Characteristics of Functional Impairment in Patients with Long-Standing Rheumatoid Arthritis Based on Range of Motion of Joints: Multicenter Prospective Cohort Study for Evaluation of Joint Surgery on Physical Function

Rheumatoid Arthritis – Clinical Aspects - Poster I: Clinical Characteristics/Presentation/Prognosis

9:00AM-11:00AM: Abstract Number: 281

Characterization of Anti-3-Hydroxy-3-Methylglutaryl Coenzyme a Reductase Autoantibodies in Juvenile Idiopathic Inflammatory Myopathies

Muscle Biology, Myositis and Myopathies - Poster I: Basic/Translational

9:00AM-11:00AM: Abstract Number: 265

Characterization of Eye Sarcoidosis with or without Systemic Involvement: Application of Iwos Criteria in an Uveitis Unit

Miscellaneous Rheumatic and Inflammatory Diseases - Poster I

9:00AM-11:00AM: Abstract Number: 237

Characterization of Peripheral Lymphocyte Phenotype in Patients with IgG4-Related Disease

Miscellaneous Rheumatic and Inflammatory Diseases - Poster I

9:00AM-11:00AM: Abstract Number: 76

Chromatin Interactions Reveal Novel Gene Targets for Drug Repositioning in Rheumatic Diseases

Genetics, Genomics and Proteomics - Poster I

9:00AM-11:00AM: Abstract Number: 371

Chronic Pain in Children Seen at a Rheumatology Clinic: Healthcare Utilization Patterns

Pain – Basic and Clinical Aspects - Poster

9:00AM-11:00AM: Abstract Number: 595

Cinical Responses and Improvements in Patient-Reported Outcomes Are Associated with Increased Productivity in the Workplace and at Home in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster I

9:00AM-11:00AM: Abstract Number: 891

Clinal Characterisitics and Diagnosis of Patients with Negative Temporal Artery Biopsy and without a Final Diagnosis of Giant Cell Arteritis

Vasculitis - Poster I: Large Vessel Vasculitis and Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 620

Clinical Activity, Ultrasound Assessment and Drug Monitoring in Rheumatoid Arthritis Patients Receiving Anti-TNF-α Therapy with Extended Interval of Administration

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster I

9:00AM-11:00AM: Abstract Number: 347

Clinical Analysis of Tumor-Induced Osteomalacia Misdiagnosed As Spondyloarthritis: A Report of 18 Cases

Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis - Poster

9:00AM-11:00AM: Abstract Number: 627

Clinical and Immunogenicity Outcomes after Switching Treatment from Innovator Infliximab to Biosimilar Infliximab in Rheumatic Diseases in Daily Clinical Practice

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster I

9:00AM-11:00AM: Abstract Number: 745

Clinical and Laboratory Correlates of Response in a Phase 3 Clinical Trial of Belimumab or Placebo Administered Subcutaneously Plus Standard Care to Patients with Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster I: Clinical Trial Design and Current Therapies

9:00AM-11:00AM: Abstract Number: 242

Clinical and Laboratory Features of IgG4-Related Retroperitoneal Fibrosis/Periarteritis in Japan: Retrospective Multicenter Study of 99 Cases

Miscellaneous Rheumatic and Inflammatory Diseases - Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].